Clinical Trial

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

Name: ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection — clinical trial record (NCT07513285)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

Protocol Amendment History 2 changes

critical Recruitment opened 2026-08-13

notable Trial sites expanded: 0 -> 15 locations 2026-08-13

Trial Details

NCT Number	NCT07513285
Lead Sponsor	Acurx Pharmaceuticals Inc.
Conditions	Clostridium Difficile Infection Recurrence
Enrollment	20 participants
Start Date	2026-08-06
Primary Completion	2027-09-29 (estimated)
Study Completion	2027-11-24 (estimated)
Updated on ClinicalTrials.gov	2026-08-12